A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?
Authorsvan Griensven, Johan
Zijlstra, Ed E
MetadataShow full item record
JournalPLoS Neglected Tropical Diseases
AbstractIn the wake of the HIV epidemic, visceral leishmaniasis (VL), a disseminated protozoan infection caused by the Leishmania donovani complex, has been re-emerging, particularly in North Ethiopia where up to 40% of patients with VL are co-infected with HIV. Management of VL in HIV co-infection is complicated by increased drug toxicity, and high treatment failure and relapse rates with all currently available drugs, despite initiation of antiretroviral treatment. Tackling L. donovani infection before disease onset would thus be a logical approach. A screen-and-treat approach targeting latent or the early stage of infection has successfully been implemented in other HIV-associated opportunistic infections. While conceptually attractive in the context of VL-HIV, the basic understanding and evidence underpinning such an approach is currently lacking. Prospective cohort studies will have to be conducted to quantify the risk of VL in different risk groups and across CD4 cell count levels. This will allow developing clinical prognostic tools, integrating clinical, HIV and Leishmania infection markers. Interventional studies will be needed to evaluate prophylactic or pre-emptive treatment strategies for those at risk, ideally relying on an oral (combination) regimen. Issues like tolerability, emergence of resistance and drug interactions will require due attention. The need for maintenance therapy will have to be assessed. Based on the risk-benefit data, VL risk cut-offs will have to be identified to target treatment to those most likely to benefit. Such a strategy should be complemented with early initiation of antiretroviral treatment and other strategies to prevent HIV and Leishmania infection.
PublisherPublic Library of Science
- Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.
- Authors: Cota GF, de Sousa MR, de Assis TSM, Pinto BF, Rabello A
- Issue date: 2017 Aug
- Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
- Authors: ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN
- Issue date: 2008 Jun 1
- High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran.
- Authors: Rezaei Z, Sarkari B, Dehghani M, Layegh Gigloo A, Afrashteh M
- Issue date: 2018 Aug
- Visceral Leishmaniasis and HIV coinfection in East Africa.
- Authors: Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J
- Issue date: 2014 Jun
- Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.
- Authors: van Griensven J, Simegn T, Endris M, Diro E
- Issue date: 2018 Feb